title: Precision medicine in pheochromocytoma and paraganglioma: current and future concepts.
abstract: Pheochromocytoma and paraganglioma (PPGL) are rare diseases but are also amongst the most characterized tumour types. Hence, patients with PPGL have greatly benefited from precision medicine for more than two decades. According to current molecular biology and genetics-based taxonomy, PPGL can be divided into three different clusters characterized by: Krebs cycle reprogramming with oncometabolite accumulation or depletion (group 1a); activation of the (pseudo)hypoxia signalling pathway with increased tumour cell proliferation, invasiveness and migration (group 1b); and aberrant kinase signalling causing a pro-mitogenic and anti-apoptotic state (group 2). Categorization into these clusters is highly dependent on mutation subtypes. At least 12 different syndromes with distinct genetic causes, phenotypes and outcomes have been described. Genetic screening tests have a documented benefit, as different PPGL syndromes require specific approaches for optimal diagnosis and localization of various syndrome-related tumours. Genotype-tailored treatment options, follow-up and preventive care are being investigated. Future new developments in precision medicine for PPGL will mainly focus on further identification of driver mechanisms behind both disease initiation and malignant progression. Identification of novel druggable targets and prospective validation of treatment options are eagerly awaited. To achieve these goals, we predict that collaborative large-scale studies will be needed: Pheochromocytoma may provide an example for developing precision medicine in orphan diseases that could ultimately aid in similar efforts for other rare conditions.
authors.affiliation: Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
authors.forename: P
authors.initials: P
authors.lastname: Björklund
authors.affiliation: Section on Medical Neuroendocrinology, Program in Reproductive and Adult Endocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA.
authors.forename: K
authors.initials: K
authors.lastname: Pacak
authors.affiliation: Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
authors.forename: J
authors.initials: J
authors.lastname: Crona
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D002952:Citric Acid Cycle / Q000235:genetics; D006801:Humans; D010235:Paraganglioma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D010673:Pheochromocytoma / Q000175:diagnosis / Q000235:genetics* / Q000628:therapy*; D011086:Polycythemia / Q000235:genetics; D057285:Precision Medicine; D015398:Signal Transduction; D013577:Syndrome; D006623:von Hippel-Lindau Disease / Q000235:genetics
keywords: cancer metabolism; neuroendocrine tumours; paraganglioma; personalized medicine; pheochromocytoma; precision medicine